• Contact Us
GI Dynamics
  • Home
  • Company
    • Who We Are
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • Financial Information
    • Corporate Governance
    • Investor Resources
  • Press
    • Press Releases
    • GID in the Media
    • Publications & Abstracts
Select Page

GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results

Aug 14, 2017 | Events

August 14, 2017 06:00 PM EDT

Webcast Presentation

Supporting Materials

Audo

Press Releases

8/12

GI Dynamics Announces FDA Approval for EndoBarrier Pivotal Trial
7/8

Association of British Clinical Diabetologists Releases First Worldwide EndoBarrier Benefit – Risk Report

 BOSTON and SYDNEY — 9 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is...
7/3

NHS EndoBarrier Service Shows Patients Maintain Treatment Effect Six Months Post Explant

 BOSTON and SYDNEY — 4 July 2018 — GI Dynamics® Inc. (ASX: GID), a medical device company that is...
  • Home
  • Company
  • Investors
  • Press

 

  1. Copyright Info
  2. Terms of Use
  3. Privacy Policy
  4. Patents

 

CAUTION: EndoBarrier is not approved for sale in the European Union or in the United States and is limited by Federal (US) Law to investigational use only. 
 

   

P.O. Box 51915 Boston, MA 02205
Email: info@gidynamics.com

  • Home
  • Company
  • Investors
  • Press

Designed by Elegant Themes | Powered by WordPress